Paradigm Diagnostics

Paradigm Diagnostics is an innovative precision medicine company that utilizes its bioinformatics and proprietary sequencing technologies to perform Paradigm Cancer Diagnostic (PCDx), which identifies the best evidence-based treatments to improve progression-free survival for cancer patients. Paradigm Cancer Diagnostic (PCDx) is groundbreaking, delivering faster diagnostic and next-generation sequencing (NGS) results (within 3-5 working days), including mutational load from a single slide. In an independent prospective study, clinical evidence has shown that using PCDx to help guide treatment decisions significantly improves progression-free survival. PCDx: Personalized Cancer Treatment. Through next-generation sequencing (NGS) and other biomarker analyses, the Paradigm Cancer Diagnostic (PCDx) test provides genomic and proteomic information about the patient's cancer, enabling oncologists to personalize each patient’s treatment plan. This molecular profiling offers broad-spectrum analysis covering 250 tested alterations, including DNA mutations, DNA copy number variations, fusions, isoforms via NGS, and proteins via IHC. PCDx results are correlated with the latest evidence on therapeutic associations.